Abstract
Abstract: The advent of a new treatment strategy in the form of disease-modifying therapy for Alzheimer’s disease (AD) has been finally achieved after a prolonged wait. Lecanemab is one of such drugs that target the pathophysiology of the disease by lowering the amyloid-β plaques to change the course of this debilitating disease and to decline its further progress. It is a humanized IgG1 monoclonal antibody that was approved by the Food and Drug Administration in July 2023 for the treatment of patients with early AD and in patients with mild cognitive impairment or mild dementia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
